Moderna Vaccine Production Is Gearing Up, Partner Lonza Says
- Company has made first batch of main ingredient in Covid shot
- Ramping up production on vaccine could last into 2021
This article is for subscribers only.
Lonza Group AG made its first commercial batch of the main ingredient in Moderna Inc.’s Covid-19 vaccine candidate in the U.S. last week and plans to start European production by the end of the month, Chairman Albert Baehny said.
The company is ramping up and fine-tuning its production lines, a process that may stretch into next year.